STATE OF NEW YORK

2030

2021-2022 Regular Sessions

IN ASSEMBLY

January 14, 2021

Introduced by M. of A. L. ROSENTHAL, QUART, RICHARDSON, CARROLL, WEPRIN, SIMON, GOTTFRIED, HEVESI -- read once and referred to the Committee on Health

AN ACT to amend the social services law and the public health law, in relation to medication for the treatment of substance use disorders

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

1	Section 1. Subdivision 2 of section 365-a of the social services law
2	is amended by adding a new paragraph (gg) to read as follows:
3	(gg) all buprenorphine products, methadone or long acting injectable
4	naltrexone for detoxification or maintenance treatment of a substance
5	use disorder prescribed according to generally accepted national profes-
6	sional guidelines for the treatment of a substance use disorder. Such
7	medication assisted treatment shall not be subject to any prior authori-
8	zation mandate.
9	§ 2. Subdivision 26-b of section 364-j of the social services law, as
10	added by section 4 of part B of chapter 69 of the laws of 2016, is
11	amended to read as follows:
12	26-b. Managed care providers shall not require prior authorization for
13	[an initial or renewal prescription for buprenorphine or injectable
14	naltrexone for detoxification or maintenance treatment of opioid
15	addiction unless the prescription is for a non-preferred or non-formu-
16	lary form of the drug or as otherwise required by section 1927(k)(6) of
17	the Social Security Act] any buprenorphine products, methadone or long
18	acting injectable naltrexone for detoxification or maintenance treatment
19	of a substance use disorder prescribed according to generally accepted
20	national professional guidelines for the treatment of a substance use
21	<u>disorder</u> .
22	§ 3. Subdivision 10 of section 273 of the public health law, as
23	amended by section 7 of part GG of chapter 56 of the laws of 2020, is
24	amended to read as follows:

EXPLANATION--Matter in <u>italics</u> (underscored) is new; matter in brackets [-] is old law to be omitted.

LBD00371-02-1

A. 2030

10. Prior authorization shall not be required for [an initial or 1 2 renewal prescription for buprenorphine or injectable naltrexone for 3 detoxification or maintenance treatment of opioid addiction unless the 4 prescription is for a non-preferred or non-formulary form of such drug 5 as otherwise required by section 1927(k)(6) of the Social Security Act. 6 Further, prior authorization shall not be required for] any buprenor-7 phine products, methadone, [when used for opioid use disorder and admin-8 istered or dispensed in an opioid treatment program] or long acting 9 injectable naltrexone for detoxification or maintenance treatment of a substance use disorder prescribed according to generally accepted 10 11 national professional guidelines for the treatment of a substance use 12 <u>disorder</u>. § 4. This act shall take effect on the ninetieth day after it shall 13

14 have become a law; provided, however, that the amendments to subdivision 15 26-b of section 364-j of the social services law made by section two of 16 this act shall not affect the repeal of such section, and shall be 17 deemed repealed therewith.